Biogen Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

BiogenDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -27.6% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsatzerlöse sind rückläufig mit einer durchschnittlichen Rate von 9.6% pro Jahr. Biogen Die Eigenkapitalrendite des Unternehmens beträgt 7.7%, und die Nettomargen liegen bei 12.1%.

Wichtige Informationen

-27.6%

Wachstumsrate der Gewinne

-20.6%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	-9.6%
Eigenkapitalrendite	7.7%
Netto-Marge	12.1%
Letzte Ertragsaktualisierung	31 Mar 2024

Jüngste Aktualisierungen vergangener Leistungen

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Feb 21

Recent updates

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

May 23

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Apr 29

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Apr 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Oct 21

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Oct 03

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Jul 16

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Jun 28

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Apr 14

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Mar 27

Aufschlüsselung der Einnahmen und Ausgaben

Wie Biogen Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:BIIB Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
31 Mar 24	9,663	1,167	2,476	2,333
31 Dec 23	9,836	1,161	2,502	2,458
30 Sep 23	9,993	1,462	2,537	2,490
30 Jun 23	9,972	2,665	2,347	2,303
31 Mar 23	10,105	3,131	2,379	2,248
31 Dec 22	10,173	3,047	2,409	2,229
30 Sep 22	10,363	2,865	2,570	2,325
30 Jun 22	10,634	2,059	2,661	2,478
31 Mar 22	10,820	1,450	2,726	2,535
31 Dec 21	10,982	1,556	2,680	2,497
30 Sep 21	11,101	1,546	2,700	3,522
30 Jun 21	11,698	1,918	2,619	3,960
31 Mar 21	12,604	3,012	2,536	4,023
31 Dec 20	13,445	4,001	2,516	3,985
30 Sep 20	14,263	5,082	2,370	2,949
30 Jun 20	14,487	5,927	2,351	2,348
31 Mar 20	14,422	5,879	2,365	2,178
31 Dec 19	14,378	5,889	2,359	2,273
30 Sep 19	14,233	5,396	2,285	2,193
30 Jun 19	14,072	5,294	2,229	2,160
31 Mar 19	13,812	4,667	2,176	2,664
31 Dec 18	13,453	4,431	2,109	2,597
30 Sep 18	13,234	3,187	2,070	2,573
30 Jun 18	12,872	2,968	2,007	2,512
31 Mar 18	12,594	2,964	1,921	2,327
31 Dec 17	12,274	2,539	1,936	2,254
30 Sep 17	11,839	3,486	1,859	2,200
30 Jun 17	11,717	3,293	1,887	2,283
31 Mar 17	11,533	3,480	1,949	1,959
31 Dec 16	11,449	3,703	1,950	1,973
30 Sep 16	11,416	3,885	2,035	1,981
30 Jun 16	11,238	3,818	2,051	1,972
31 Mar 16	10,936	3,695	2,050	1,990
31 Dec 15	10,764	3,547	2,113	2,013
30 Sep 15	10,565	3,599	2,104	1,971
30 Jun 15	10,299	3,490	2,196	1,869
31 Mar 15	10,128	3,277	2,281	1,825
31 Dec 14	9,703	2,935	2,232	1,893
30 Sep 14	9,028	2,509	2,154	1,816
30 Jun 14	8,345	2,139	1,990	1,808
31 Mar 14	7,647	1,916	1,844	1,689
31 Dec 13	6,932	1,862	1,712	1,444
30 Sep 13	6,384	1,697	1,565	1,367
30 Jun 13	5,942	1,608	1,459	1,261

Qualität der Erträge: BIIB hat einen großen einmalig Verlust von $572.6M, der sich auf die Finanzergebnisse der letzten 12 Monate auswirkt, an 31st March, 2024.

Wachsende Gewinnspanne: BIIBDie aktuellen Gewinnspannen (12.1%) sind niedriger als im letzten Jahr (31%).

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: BIIBDie Erträge des Unternehmens sind in den letzten 5 Jahren um 27.6% pro Jahr zurückgegangen.

Beschleunigtes Wachstum: BIIBDas Unternehmen hat im vergangenen Jahr ein negatives Gewinnwachstum verzeichnet, so dass es nicht mit seinem 5-Jahres-Durchschnitt verglichen werden kann.

Erträge im Vergleich zur Industrie: BIIB hatte im vergangenen Jahr ein negatives Gewinnwachstum (-62.7%), was einen Vergleich mit dem Branchendurchschnitt Biotechs (-14.4%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: BIIBDie Eigenkapitalrendite des Unternehmens (7.7%) wird als niedrig angesehen.

Biogen Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Biogen Inc. (NasdaqGS:BIIB) agreed to acquire Human Immunology Biosciences, Inc. from Alpha Wave Global, LP, Jeito Capital S.A., Viking Global Investors LP and others for approximately $1.8 billion.

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

Pomerantz LLP Announces Filing of a Class Action against Biogen Inc

Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis

Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (Lecanemab-Irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track Status

Biogen's Revenue Dip Meets Cost Cuts In Q1 (Rating Upgrade)

Earnings Update: Biogen Inc. (NASDAQ:BIIB) Just Reported Its First-Quarter Results And Analysts Are Updating Their Forecasts

Biogen Inc., Annual General Meeting, Jun 20, 2024

Biogen Inc. Receives Positive CHMP Opinion for TOFIDence (tocilizumab), a Biosimilar Referencing ROACTEMRA

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Biogen Inc. Provides Earnings Guidance for the Full Year of 2024

The Price Is Right For Biogen Inc. (NASDAQ:BIIB)

Biogen Inc. to Report Q1, 2024 Results on Apr 24, 2024

We Think You Can Look Beyond Biogen's (NASDAQ:BIIB) Lackluster Earnings

Consensus EPS estimates fall by 11%

Biogen Inc. Just Missed EPS By 21%: Here's What Analysts Think Will Happen Next

Biogen's Q4 Earnings Disappoint Amidst Strategic Challenges (Rating Downgrade)

Full year 2023 earnings: EPS misses analyst expectations

Biogen Inc. Announces Plans to Reprioritize its Resources in Alzheimer’s Disease, Strategic Therapeutic Area Expected to Drive Near and Long-Term Growth

Here's Why Biogen (NASDAQ:BIIB) Can Manage Its Debt Responsibly

Consensus EPS estimates increase by 11%

Biotech And Pharma Diversification Pays Off

Biogen Inc. to Report Q4, 2023 Results on Feb 13, 2024

Getting In Cheap On Biogen Inc. (NASDAQ:BIIB) Might Be Difficult

CHMP Issues Positive Opinion for Biogen Inc.'s SKYCLARYS(R) (omaveloxolone), the First Therapy to Treat Friedreich's Ataxia

Sage Therapeutics, Inc. and Biogen Inc. Announces ZURZUVAE (Zuranolone) 50 mg (Two 25 mg Capsules Per Day) CIV

Biogen Inc. Updates Revenue Guidance for the Fiscal Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 23%

Biogen Inc. Appoints Monish Patolawala to Its Board of Directors, Effective from January 1, 2024

Eisai Co., Ltd. and Biogen Inc. announces Eisai presented new data for LEQEMBI® (lecanemab-irmb) 100 mg/mL injection for intravenous (IV) use, in the Late Breaking Symposium 4 ‘Lecanemab for Early Alzheimer's Disease

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 49% Undervalued

Biogen Inc. to Report Q3, 2023 Results on Nov 08, 2023

Is Biogen (NASDAQ:BIIB) Using Too Much Debt?

FDA Approves Biogen Inc.'s TOFIDENCE™ (tocilizumab-bavi), a Biosimilar Referencing ACTEMRA®

Biogen Inc. (NasdaqGS:BIIB) acquired Reata Pharmaceuticals, Inc. (NasdaqGM:RETA).

Eisai Co., Ltd. and Biogen Inc. Announces LEQEMBI Intravenous Infusion (Lecanemab) Approved for the Treatment of Alzheimer’S Disease in Japan

Dr Reddy's Laboratories Reportedly Jumps into the Fray for Biogen's Biosimilars

Biogen Inc. Announces the Appointment of Jane Grogan, Ph.D., as Executive Vice President, Head of Research Effective 2 October 2023

Sanofi Reportedly Second Bidder for Reata

Biogen Inc. (NasdaqGS:BIIB) entered into a definitive agreement to acquire Reata Pharmaceuticals, Inc. (NasdaqGM:RETA) from shareholders for approximately $7 billion.

Biogen Inc. Reaffirms Earnings Guidance for the Full Year of 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Eisai Co., Ltd. and Biogen Inc. Present Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023

Is Biogen Inc. (NASDAQ:BIIB) Trading At A 31% Discount?

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Biogen Inc. to Report Q2, 2023 Results on Jul 25, 2023

Eisai Co., Ltd. and Biogen Inc. Announces FDA Grants Traditional Approval for LEQEMBI® (Lecanemab-Irmb) for the Treatment of Alzheimer’s Disease

Biogen (NASDAQ:BIIB) Has A Pretty Healthy Balance Sheet

Biogen Announces Board Changes

Biogen Inc., Annual General Meeting, Jun 26, 2023

Biogen Inc., Annual General Meeting, Jun 26, 2023

Now 22% undervalued

Biogen Inc., Annual General Meeting, Jun 26, 2023

Eisai Co., Ltd. and Biogen Inc. Announces the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee

Eisai Co., Ltd. and Biogen Inc. Announce Health Canada Accepts New Drug Submission for Lecanemab

Now 20% undervalued

Insider recently sold US$804k worth of stock

Insider notifies of intention to sell stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

An Intrinsic Calculation For Biogen Inc. (NASDAQ:BIIB) Suggests It's 23% Undervalued

Is Biogen (NASDAQ:BIIB) A Risky Investment?

Now 21% undervalued after recent price drop

Executive VP exercised options and sold US$259k worth of stock

Consensus EPS estimates fall by 11%, revenue upgraded

Executive VP exercised options and sold US$415k worth of stock

Biogen Inc. Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Biogen Inc. and Sage Therapeutics, Inc. Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression